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Abstract 
The logical and practical difficulties associated with research interpretation using P values 
and null hypothesis significance testing have been extensively documented. This paper 
describes an alternative, likelihood-based approach to P-value interpretation. The P-value and 
sample size of a research study are used to derive a likelihood function with a single 
parameter, the estimated population effect size, and the method of maximum likelihood 
estimation is used to calculate the most likely effect size. Comparison of the likelihood of the 
most likely effect size and the likelihood of the minimum clinically significant effect size 
using the likelihood ratio test yields the clinical significance support level (or S-value), a 
logical and easily understood metric of research evidence. This clinical significance 
likelihood approach has distinct advantages over null hypothesis significance testing. As 
motivating examples we demonstrate the calculation and interpretation of S-values applied to 
two recent widely publicised trials, WOMAN from the Lancet and RELIEF from the New 
England Journal of Medicine. 
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1. INTRODUCTION 
Null hypothesis significance testing (NHST) has become entrenched as the dominant 
paradigm of research study interpretation despite possessing a number of short-comings.1,2 
These have been extensively documented over many years, but in particular we highlight the 
following three limitations of NHST.3  Firstly, P-values are consistently misunderstood by 
end-users; secondly, results that fail to achieve statistical significance are difficult to 
interpret; and thirdly, the non-equivalence of statistical and clinical significance is often not 
appreciated by the reader. This paper describes the clinical significance likelihood method, a 
likelihood-based approach to P-value interpretation that addresses these three limitations. It 
involves derivation of a likelihood function using the P-value and sample size of a research 
study, generation of a maximum likelihood estimate of the effect size, and comparison of this 
estimate to the minimum clinically significant effect size (MCSES) to obtain the clinical 
significance support level (S-value) – a novel and easily understood measure of the strength 
of evidence supporting the existence of a clinically significant effect. 
2. DERIVATION OF THE LIKELIHOOD FUNCTION 
 We concern ourselves with a common task in the interpretation of the biomedical 
literature: the drawing of inference from a comparison of two study arms that generates a P 
value. In this paper we shall consider the case where the parameter of interest is an 
approximately normal continuous variable but note that it is possible to derive a similar 
likelihood function for any statistical test returning a P-value if there exists an appropriate 
power function. Thus included are P values derived from the binomial and Poisson 
distributions, correlation, and analysis of variance. In essence, the P-value provides the type I 
error rate (false positive), the power function provides the type II error rate (false negative), 
and these are combined using Bayes theorem.  
We designate δ as the standardized effect size of the parameter of interest, (that is, the 
effect size divided by its standard deviation). The null hypothesis is assumed to be an effect 
size of zero. We consider the P-value (P) calculated from the results of such a study and 
define P less than α as a ‘positive’ result and P greater than or equal to α as a ‘negative’ 
result, α being an arbitrarily pre-defined threshold for the P-value. Traditionally α = 0.05 has 
been used in biomedical research but there is no theoretical reason why any other value 
cannot be used. The likelihood ratio form of Bayes’ theorem can be expressed as 𝐿𝑅! =  𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦(𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒)𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦(𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒)  ,  𝐿𝑅! =  𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦(𝑓𝑎𝑙𝑠𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒)𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑡𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒  
LR+ and LR- being the positive and negative likelihood ratios respectively. We set α to be 
equivalent to P: this has several important effects. Firstly, it makes the probability of a true 
positive result equivalent to the power (γ) of the study; power being defined as the probability 
of obtaining a ‘positive’ result if the null hypothesis is false. Secondly, it makes the 
probability of a false positive result equivalent to the P-value of the study, the P-value being 
the probability of obtaining a ‘positive’ result if the null hypothesis is true, and thus 𝐿𝑅! =  !!  , 𝐿𝑅! =  !!!!!!  [1] 
Thirdly, since α = P, the derived P-value for the study lies exactly at the junction between a 
‘positive’ and ‘negative’ result. The likelihood ratio at this point is the product of the positive 
and negative likelihood ratios.4 This can be illustrated graphically by plotting the probability 
of a false positive result against the probability of a false negative result producing a ROC 
curve; the likelihood at any point on the curve equals the slope of the tangent at that point. 
Hence from equation 1 𝐿𝑅! = 𝐿𝑅! × 𝐿𝑅! = !!!!!!!!  [2] 
Where LRδ is the likelihood ratio for a particular effect size and γ is the marginal power in 
this case calculated using the two-sided power function for a normally distributed continuous 
variable: 𝛾 = 1− 𝜙 𝑍 !!!! − 𝛿 𝑛 + 𝜙(−𝑍 !!!! − 𝛿 𝑛) [3] 
where ϕ(.) is the cumulative distribution function of the normal distribution, Z(.) is the 
inverse of the cumulative distribution function of the normal distribution, n is the sample size, 
and δ is the standardized effect size.  
A key part of the derivation of equation 2 is the setting of α=P to obtain the marginal 
power, a step which requires justification. The parameter α has two distinct roles; firstly it 
determines the cut-off point between a significant and a non-significant result, and secondly it 
determines the long run false positive rate. We are interested only in the former role, the latter 
belonging to the frequentist approach that does not figure in the likelihood paradigm.5 The 
cut-off point is important in the context of equation 1. It is axiomatic that the positive 
likelihood ratio should be greater than one, and that the negative likelihood ratio should be 
less than one. From equation 1 it can be seen that this implies that γ must always be greater 
than or equal to P. The only way to guarantee this is to set α=P, because from the power 
function, γ≥α is always true. This can be demonstrated using equation 3 where setting n=0 
minimises power, hence:  𝛾!"# = 1− 𝜙 𝑍 !!!! + 𝜙 −  𝑍 !!!!   
and given that for any value x 𝜙 𝑍! = 𝑥    𝑎𝑛𝑑   𝜙 −𝑍! = 1− 𝑥 
hence 𝛾 = 1− 1− 𝛼2 + 1− 1− 𝛼2 = 𝛼 
thus γ=α when n=0, and γ>α when n>0 since giving any positive value to the moiety δ√n will 
increase γ. It is worth pointing out that γ (the marginal power) in equation 3 is not the same as 
observed (or post-hoc) power. Observed power is obtained by substituting the observed effect 
size for δ,6 whereas marginal power is obtained by substituting the P-value for α. 
It could be reasonably argued that the P-value and marginal power as tail areas of the 
sampling distribution do not truly represent the false positive and true positive probabilities 
respectively7. However, consider some function g(.) such that  𝑔 Prob 𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 = 𝑃, 𝑎𝑛𝑑  𝑔 Prob 𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 = 𝛾 
hence 
𝐿𝑅! = 𝑔!! 𝛾𝑔!! 𝑃 =  𝛾𝑃 
In other words, the tail area to probability transform applies to both P and γ and equation 1 
thus holds. 
The likelihood ratio obtained from equations 2 and 3 represents the ratio of the 
probability that the true effect size equals the pre-specified value to the probability that the 
true effect size equals zero. Since the post-study P-value and sample size are fixed and 
known, it represents a likelihood function with a single parameter, the effect size (δ). The 
validity of this approach has been previously demonstrated by the accurate calculation of 
expected P-values.8 	
3. ESTIMATION AND PROPERTIES OF THE MOST LIKELY EFFECT SIZE (MLES) 
 Given the likelihood function we can use the method of maximum likelihood 
estimation to estimate the most likely value for the effect size parameter: the most likely 
effect size (MLES). As the P-value is fixed and known post-study, from equation 2 it is clear 
that the likelihood ratio is maximized when γ = 0.5, hence re-arranging equation 3, the MLES 
is that value of δ that satisfies 0.5 = 𝜙 𝑍 !!!! − 𝛿 𝑛 − 𝜙(−𝑍 !!!! − 𝛿 𝑛)  [4] 
This equation has no solution when P≥0.5. In these circumstances the value of δ that 
minimizes the difference between γ and 0.5 and hence maximises the likelihood ratio is 
always zero. Thus MLES=0 when P≥0.5 (Figure 1). 
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Figure 1. Illustrative likelihood function curves. Assuming the minimum clinically significant 
effect size (MCSES) = 0.2, for each of these curves the S-values  are A) 37.5%, B) 1.5%, C) 
88%, D) 27.5%, representing the level of support provided for the supposition that MLES is 
greater than MCSES. 
 
When P<0.5, the MLES is always non-zero and equation 4 is not algebraically 
solvable so graphical or iterative methods must be used. Using these empirical methods it can 
be demonstrated that for reasonably large sample size (n>30), as P gets smaller the relative 
value of the second term on the right hand side of equation 4 becomes insignificant. Under 
these conditions and with this second term ignored, equation 4 can be rewritten as 
𝑀𝐿𝐸𝑆 = 𝑍(!!!!) 𝑛  [5] 
in which case the MLES is equivalent to the observed study effect size, as expected (Figure 
2).  
 
 
 
Figure 2. Most likely effect size (MLES) and P value at varying sample sizes, with a fixed 
observed standardized effect size of 0.6. 
It is instructive to demonstrate some of the properties of the MLES, in particular its 
likelihood-based support intervals.9 Because the MLES is a maximum likelihood estimate we 
can calculate the 95% likelihood interval for the effect size using the likelihood ratio method, 
the upper and lower limits being the values where the likelihood ratio equals approximately 
14.65% of the likelihood ratio of the MLES. This can be determined algebraically only if 
P<0.2 (see figure 2) and the sample size is reasonably large (n>30). From equation 2 (given 
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the LR is maximised when the numerator =0.25) the limits of the 95% likelihood interval 
(LRLI) are given by 𝐿𝑅!" = !.!"×!.!"#$!!!! = !.!"#!!!!  [6] 
Hence 𝛾 − 𝛾! = 0.037 ⇒  𝛾 = 0.038 𝑎𝑛𝑑 𝛾 = 0.962   [7] 
The likelihood function is asymmetric so it is only possible to algebraically calculate the 
upper value of δ for the limit (δLI). Using equation 3 and again ignoring the second term on 
the right hand side 𝛿!" = (𝑍(!!!!) + 1.77)/ 𝑛  [8] 
Hence the upper bound of the 95% likelihood interval of the MLES is +1.77/√n (given P<0.2 
and n>30). When algebraic calculation of the MLES is not possible iterative approximation 
or graphical methods must be used. Using these methods the following can be demonstrated: 
a) When P≥0.5 the upper 95% bound of the likelihood interval of the MLES is given by 𝑢𝑝𝑝𝑒𝑟95% 𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙 = 𝑀𝐿𝐸𝑆 + 2.96− 𝑃𝑛  
b) When P<0.5 the upper 95% bound of the likelihood interval of the MLES asymptotically 
approaches (MLES + 1.77√n)  
c) The lower 95% bound of the likelihood interval of the MLES cannot be accurately 
determined when it overlaps zero. The P-value and power function are directionally agnostic, 
and thus the likelihood function is undefined when the effect size is negative.10 In these 
circumstances it is sufficient to state that the 95% likelihood interval includes zero and a 
negative effect size.  
The above properties of the MLES are a consequence of the derivation of the likelihood 
function using the P-value. As described originally by Ronald Fisher, calculation of a P-value 
includes the implied initial assumption that the null hypothesis is true. Hence the MLES is 
zero when P<0.5 and there is an intrinsic bias in favour of the null hypothesis. This bias is 
consistent with Popper’s concept of empirical falsification and can therefore be considered as 
a desirable property of this likelihood function. 
 
4. CALCULATION OF THE CLINICAL SIGNIFICANCE SUPPORT LEVEL (S-VALUE) 
The likelihood ratio test can be used to compare hypotheses using the likelihood 
function.11 If the hypotheses are defined with reference to the parameter space of the effect 
size, then the likelihood ratio statistic (λ) is defined as: 𝜆 = −2ln [! !"#!!! !"#!! ]  [9] 
where MLEH1 and MLEH2 are the maximum likelihood estimates for the respective parameter 
spaces of H1 and H2. In our case we consider H2 to be a composite hypothesis encompassing 
the whole parameter space, and H1 to be a nested composite hypothesis encompassing only 
those values of delta that exceed the minimum clinically significant effect size (MCSES). 
Therefore, to test the hypothesis that MLES is greater than the MCSES,  𝜆 =  −2ln (!"#!"#$#!"#!"#$ )  [10] 
The likelihood ratio statistic (λ) has a chi-squared distribution with one degree of freedom 
under these conditions (Wilks’ theorem), and letting Κ denote the percentage point of this 
distribution for the value λ, we define the clinical significance support level (S-value) as  
𝑆 =    𝛫 + !!!! , 𝑖𝑓 𝑀𝐿𝐸𝑆 > 𝑀𝐶𝑆𝐸𝑆  !!!! ,               𝑖𝑓 𝑀𝐿𝐸𝑆 < 𝑀𝐶𝑆𝐸𝑆    0.5,              𝑖𝑓 𝑀𝐿𝐸𝑆 = 𝑀𝐶𝑆𝐸𝑆  [11] 
It has been established from Wilks’ theorem that the likelihood ratio test, although robust, is 
only asymptotically optimal as n ->∞ and hence may not be applicable to small samples.12 
However if a likelihood function is regular and the quadratic approximation is good then the 
theorem still holds even with small sample sizes.13 Observing Figure 1 it is clear that the 
likelihood function is regular except when the P-value is large and the standardized effect 
size is small. Hence, under conditions of large p-value plus small sample size plus effect size, 
S-values may not be accurate, but otherwise a good approximation will be obtained. 
The S-value represents a one-sided likelihood interval. It is a purely data-driven 
likelihood inferential statistic and represents the degree of support the data give to the 
supposition that the research study result (manifest as the MLES) is greater than the 
minimum clinically significant effect size (MCSES). The term support is deliberately chosen 
for historical reasons (A.W.F Edwards referred to the log of the likelihood function as the 
“support function”), and for its connotations. The S-value is not a frequentist one-sided 
confidence level and no long-run frequency claims are made.14 The S-value is also not a 
Bayesian statistic – no prior probability distribution is assumed so there can be no posterior 
probability distribution. In general, the likelihood function and by implication the statistics 
derived from it, allow the data to speak for itself uncontaminated by a Bayesian prior 
distribution and unconstrained by the frequentist imperative to control a long term error rate. 
Some illustrative likelihood functions and S-values for several hypothetical studies 
are shown in figure 1. We are interested in the support given to the supposition that the 
MLES is greater than the MCSES (in this case equal to 0.2). Curve A represents a relatively 
small study with a clearly non-significant P-value (P=0.4). The clinical significance support 
level (S = 37.5%) provides weak evidence against the supposition as would be expected with 
such a small sample size. Curve B on the other hand represents a larger study with the same 
non-significant P-value (P=0.4), but the clinical significance support level is much lower (S = 
1.5%) and provides strong evidence against the supposition. Curve C represents a small study 
with a significant P-value (P=0.02). The clinical significance support level is high (S = 88%) 
and provides reasonable but not conclusive evidence for the supposition. Curve D represents 
a larger study with a significant P-value but the clinical significance support level (S = 
27.5%) is inconclusive despite the larger sample size. These results illustrate the interaction 
between sample size and p-value in determining the S-value. 
 
5. ADVANTAGES OF THE CLINICAL SIGNIFICANCE LIKELIHOOD APPROACH 
The P-value represents a measure of the strength of evidence supporting a non-zero effect 
size over an effect size of zero. However an effect size of zero is seldom plausible in 
biomedical research and thus represents a reference point rather than a viable competing 
hypothesis. This is one of the weaknesses inherent in null hypothesis significance testing 
(NHST) and is apt to produce confusion for some end-users, particularly in regard to the 
distinction between a statistically significant result (that is a probable non-zero effect size) 
and a clinically significant result (that is an effect size greater than the MCSES). The S-value 
avoids this problem by directly comparing the MLES and MCSES, thus making clinical and 
statistical significance indistinguishable. 
Interpretation of non-significant P-values (P>0.05) is not well encompassed by 
classical (Fisherian) null hypothesis significance testing, these results being simply described 
as failure to reject the null hypothesis. An alternate approach is to take into consideration the 
power of a study and then reject the alternate hypothesis if the power is sufficiently high. 
There is however no clear consensus on what constitutes sufficiently high power – 95%, 90% 
and 80% have all been proposed. Whatever the level proposed, it is an unfortunate fact that 
high-powered studies are the exception rather than the rule in the biomedical literature. 
Indeed, in the field of neuroscience the mean power of published studies is less than 30%.15 
To compound this problem, many published studies either do not emphasise their statistical 
power or do not specify it at all, and a significant proportion of end-users are likely to either 
lack the ability or the motivation to calculate the power themselves. In addition, rejection of 
the alternate hypothesis when P>0.05 based on statistical power alone is illogical. The degree 
of support for the null hypothesis varies across the range of P-values 0.05 to 1.00 and this 
should logically be taken into account along with statistical power. The S-value does this and 
is able to indicate the level of evidence both for (S-value>50%) and against (S-value<50%) 
the alternate hypothesis that the true population effect size is greater than the MCSES. 
Unlike P-values, the S-value explicitly includes study power. Under NHST, if a true 
effect size exists however small, it is always possible to obtain a P-value < 0.05 with a large 
enough sample size. This occurs because P values conflate effect size and sampling error.16 
Therefore a large (non-significant) P value may be due to a small effect size or an 
insufficiently large sample size or both. Conversely, a small (significant) P value may be due 
to a large effect size or a large sample size or both. With the clinical significance likelihood 
method the opposite phenomenon occurs. If the true population effect size is less than the 
MCSES then increasing the sample size will only make the S-value smaller and decrease the 
level of support for the supposition that the true effect size exceeds the MCSES.  
It is recognised that the smaller the p-value, the stronger the evidence against the null 
hypothesis. Apart from this qualitative understanding though, it is difficult to apprehend the 
quantitative nature of this relationship – for instance, is the evidence provided by a p-value of 
0.05 twice as strong as that provided by a p-value of 0.1? The S-value however provides a 
clear indication of the strength of evidence. Its relationship to the strength of evidence is 
inverse to that of the p-value (the higher the S-value the stronger the favouring evidence) and 
is expressed as a percentage and hence seems intuitively clearer. 
Although specification of the minimum clinically significant effect size is routinely 
required for sample size estimation, it is often not emphasised in the interpretation of research 
study results. The S-value method however explicitly requires that the MCSES is specified 
along with the observed effect size in the study result. The emphasis on effect size rather than 
P-values is a desirable feature of the clinical significance likelihood method.17,18  On occasion 
a reasonable value for the MCSES may not be obvious or there may be disagreement over 
what the value should be. In this situation it may be useful to plot the S-value for a range of 
values of the MCSES as shown in figure 3. In this way, the effect of uncertainty as to the 
value of the MCSES on the S-value can be ascertained graphically. 
 
 
Figure 3. S-values for varying standardized minimum clinically significant effect size levels 
(MCSES) for a hypothetical study with a P-value of 0.1 and a sample size of 100. The most 
likely effect size (MLES) for this study is 0.16 hence the S-value equals 0.5 at this point. 
Although the title of this paper suggests the clinical significance likelihood method is 
an alternative to NHST, it can also be considered as complementary. NHST has been the 
dominant research paradigm since the middle of the last century and it seems unlikely that it 
will be abandoned in the near future. The clinical significance support method has the 
advantage that it can be calculated post-hoc without any need to alter the current methods of 
research planning or conduct. As such it can stand alongside the P-value, providing an 
additional valuable insight into the evidential import of medical research. The concept of 
likelihood based statistical inference is not new having initially been popularised by R.A 
Fisher and extended by others since. However, likelihood based methods have made little 
inroad into the fields of statistical hypothesis testing and inference in biomedicine, and NHST 
remains the dominant paradigm. This may well be due scientific cultural inertia. To 
paraphrase the American Statistical Association’s statement on P-values, everybody is taught 
NHST in universities and statistics courses because NHST is what everybody uses, and 
everybody uses NHST because that is what everybody was taught in universities and 
statistics courses.2 This self-reinforcing cultural milieu makes it very difficult for a new 
approach to be embraced, no matter its qualities and advantages, and hence likelihood based 
statistical inference remains largely unused. A clear example of this is the cogent and 
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compelling argument advanced by Royall in his monograph Statistical Evidence: a likelihood 
paradigm published more than 20 years ago which nevertheless has had minimal effect on the 
actual practice of statistical inference.19 Using the clinical significance method, P values are 
calculated as is standard and each is associated with its own S-value. We are hopeful that this 
attachment of an S-value to the familiar P-value will lessen the resistance to adoption of a 
likelihood-based method. It is of course possible to calculate an S-value directly from the 
observed effect size without use of a P-value but this approach loses this attachment and also 
the empirical falsificationist nature of the P-value.20 
 
6. TWO MOTIVATING EXAMPLEs 
Two motivating examples are included to demonstrate the methodology and 
inferential value of the clinical significance likelihood approach. The WOMAN study 
published in the Lancet in 2017 examined the effect of tranexamic acid on mortality and 
morbidity due to post-partum haemorrhage.21 The outcomes of interest were binary (dead vs 
not dead, hysterectomy vs no hysterectomy). Because the sample size was large we can use 
the normal approximation to the binomial distribution and all the equations used above are 
applicable, in particular the power equation (eq. 4), the sample size here referring to the 
number of subjects in each group. Several different effect sizes could be used (including 
relative risk and the arcsin transformation of a proportion) but we will use the absolute 
difference between two proportions divided by their standard deviation. From the study’s 
methods section the minimum clinically significant effect size for the primary outcome is a 
0.75% absolute difference in proportions, which is a standardised effect size of approximately 
0.04. A similar minimum clinically significant effect size can reasonably be assumed for the 
secondary outcomes. 
We consider first one of the secondary endpoints, death due to bleeding (n=20021) 
which favoured tranexamic acid with an observed standardized effect size of 0.02 and a P-
value of 0.045. Given the large sample size and small P-value it is unsurprising that the 
MLES is the same as the observed effect size (see equation 5 above), however this value is 
substantially less than the standardised minimum clinically significant effect size, giving an 
S-value of 2%. The large sample size in this study ensures that the likelihood function is 
narrow and peaked making effect size values that differ to any great degree from the MLES 
highly unlikely. 
Another secondary endpoint considered death due to post-partum haemorrhage in the 
sub-group (n=14886) given treatment within 3 hours, for which the observed standardised 
effect size was 0.035 (favouring the treatment arm), and the resultant P-value was 0.008 
giving an S-value of 22%. These results suggest that the true population effect size in this 
sub-group is unlikely to be zero (given P=0.008) but is also unlikely to be as large as the 
MCSES (given the S-value =22%). Thus although the P-value is statistically significant 
according to the orthodox NHST interpretation, the result does not appear to be clinically 
significant according to the study authors own benchmark (the MCSES), and in this case the 
S-value and P-value given together provide added insight compared to the P-value alone.  
Finally, the primary endpoint in the WOMAN study was death from all causes and/or 
hysterectomy (n=20060), the P-value for which was 0.65. This is clearly a ‘non-significant’ 
result, and we are unable to reject the null hypothesis (that the true population effect size is 
zero). However, this result gives us no indication of the level of support for the alternative 
hypothesis, it merely suggests that a zero effect size is not unlikely. The calculated S-value  
<1%, which indicates almost no support for the alternate hypothesis that the standardized true 
population effect size exceeds 0.04, hence based on the results of this study the alternate 
hypothesis should be rejected. 
The WOMAN trial was enthusiastically received in some quarters and was interpreted 
as providing evidential support for the administration of tranexamic acid to prevent the 
adverse outcomes associated with post-partum haemorrhage.22 Possibly this enthusiasm was 
due to the article abstract which emphasised the significant P-value for the sub-groups 
mentioned above, and not the non-significant P-value for the primary outcome. Examination 
of the results of this trial using the clinical significance likelihood method reveals a different 
story – there is close to zero support (<1%) for the primary outcome, and little support (2% 
and 22%) for the two secondary sub-group outcomes. Presentation of S-values along with P-
values might have prevented the misinterpretation. It could be argued that the minimum 
clinically significant effect size of a 0.75% reduction in death rate is too high and indeed it 
may have been chosen for pragmatic reasons to limit the sample size. This is a clinical 
question and beyond the scope of this article, but it is illustrative to consider the effect of 
varying the MCSES upon the various S-values calculated above and this is shown in Table 1 
 
MCSES  
(rate difference) 
0 0.0025 0.005 0.0075 
Primary outcome 50% 13% 1% <1% 
Mortality due to 
bleeding 
97% 75% 23% 2% 
Mortality due to 
bleeding, treatment 
given within 3 hours 
>99% 95% 65% 22% 
Table 1. S-values for various minimum clinically significant effect sizes (MCSES) from the 
WOMAN trial.21  
The RELIEF trial compared a restrictive versus liberal perioperative intravenous fluid 
regime in patients undergoing major abdominal surgery.23 The primary outcome was 
disability-free survival at 1 year assessed using the Kaplan-Meier method and expressed as a 
hazard ratio (HR). In addition, there were multiple secondary outcomes and adjustment was 
made for multiple comparisons (and for a single interim analysis) using the Holm-Bonferroni 
method. For calculation of the clinical significance support we can use equation 3, 
substituting the number of events (death or disability) for the sample size (that is n equals the 
event-rate multiplied by the number of subjects) and using the natural log of the hazard ratio 
divided by its standard deviation as the standardised effect size (δ).24 Table 2 shows the 
results for some selected outcomes. From the methods section in this paper, the MCSES for 
the primary outcome appears to be a hazard ratio of 0.80, corresponding to a standardized 
effect size of 0.11, and this value is used to determine the S-value; S-values for a range of 
other hazard ratios are shown in figure 4. As is common, no MCSES is specified for the 
secondary outcomes so we have used an outcome hazard ratio of 1.0 as a default.  
 
 
 
Outcome Restrictive 
Fluid 
(N=1490) 
Liberal Fluid 
(N=1493) 
Hazard or Risk 
Ratio 
(95% CI) 
P value S value  
 
Disability-free 
survival at 1 
year (%) 
81.9 82.3 1.05(0.88-1.24) 0.61 1% 
Surgical-site 
infection (%) 
16.5 13.6 1.22 (1.03-1.45) 0.02* 99% 
Acute kidney 
injury (%) 
8.6 5.0 1.71 (1.29-2.27) <0.001 >99% 
Renal-
replacement 
therapy (%) 
0.9 0.3 3.27 (1.01-13.8) 0.048* 97% 
Pulmonary 
oedema (%) 
1.4 2.2 0.63 (0.36-1.09) 0.1 92% 
Unplanned 
ICU 
admission 
10.8 9.7 1.11 (0.9-1.38) 0.32 70% 
Table 2. Selected outcomes from the RELIEF trial.23 The S-value is calculated using a 
minimal clinically significant hazard ratio of 0.8 for the primary outcome of disability-free 
survival, and 1.0 for other outcomes. (*Result not significant after adjustment for multiple 
comparisons within the trial). 
 
 
The MLES for the primary outcome is HR=1 given that the p-value is greater than 
0.5. The S-value is a one-sided, post-data statistics and only provides information on the 
strength of evidence in the direction of the observed effect. In this study, the data favours 
disability-free survival to be greater in the liberal fluid group. The S-value for this outcome 
measures the support for the supposition that the hazard ratio for the restrictive group 
compared to the liberal group is less than 0.8, and clearly that support is very low. The data 
for the secondary outcomes (with the exception of pulmonary oedema) clearly favour the 
liberal fluid group and the S-values reflect this. This study clearly favours a liberal fluid 
strategy with only one of 17 outcomes in favour of the restrictive approach. This is not 
reflected in the standard NHST interpretation where only one P-value is deemed significant 
after adjustment for multiple comparisons. Such adjustments are not necessary when using 
likelihood based methods.5 We feel the clinical significance method more accurately reflects 
the import of the results of this study than the standard NHST approach. 
 Figure 4. S-values for varying hazard ratios for disability-free survival as the primary 
outcome of the RELIEF trial.23 Note that a hazard ratio >1 favours the liberal fluid group. 
 
 
7. CONCLUSION 
The clinical significance support level (S-value) is a novel test statistic calculable under a 
wide range of circumstances. Input parameters are the P-value and sample size of a research 
study. The output is a readily understood, continuous measure of the strength of evidence 
supporting the hypothesis of the study. Interpretation of the S-value is intuitively simple and 
is likely to be easier for end-users than interpretation of the P-value The clinical significance 
support method avoids a number of problems associated with null hypothesis significance 
testing. 
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